CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks

eptinezumabEptinezumab
Related Companies

Read the original article

Published by PR Newswire Biotech on September 16, 2026 6:22 AM

Read Original